Posted by Michael Wonder on 25 Jul 2022
Treosulphan NDA resubmitted to FDA
25 July 2022 - Pivotal Phase 3 clinical trial of treosulphan met primary endpoint and key secondary endpoints.
Medexus Pharmaceuticals and medac, a strategic partner of Medexus, are pleased to announce that medac has resubmitted its new drug application for treosulphan with the U.S. FDA.
